A novel protective effect of erythropoietin in the infarcted heart

Cyrus J. Parsa, Akio Matsumoto, Jihee Kim, Ryan U. Riel, Laura S. Pascal, G. Brant Walton, Richard B. Thompson, Jason A. Petrofski, Brian H. Annex, Jonathan S. Stamler, Walter J. Koch

Research output: Contribution to journalArticle

Abstract

Erythropoietin (EPO) has been shown to protect neurons from ischemic stroke, but can also increase thrombotic events and mortality rates in patients with ischemic heart disease. We reasoned that benefits of EPO might be offset by increases in hematocrit and evaluated the direct effects of EPO in the ischemic heart. We show that preconditioning with EPO protects H9c2 myoblasts in vitro and cardiomyocytes in vivo against ischemic injury. EPO treatment leads to significantly improved cardiac function following myocardial infarction. This protection is associated with mitigation of myocyte apoptosis, translating into more viable myocardium and less ventricular dysfunction. EPO-mediated myocyte survival appears to involve Akt activation. Importantly, cardioprotective effects of EPO were seen without an increase in hemarocrit (eliminating oxygen delivery as an etiologic factor in myocyte survival and function), demonstrating that EPO can directly protect the ischemic and infarcted heart.

Original languageEnglish (US)
Pages (from-to)999-1007
Number of pages9
JournalJournal of Clinical Investigation
Volume112
Issue number7
DOIs
StatePublished - Oct 2003
Externally publishedYes

Fingerprint

Erythropoietin
Muscle Cells
Ventricular Dysfunction
Myoblasts
Hematocrit
Cardiac Myocytes
Myocardial Ischemia
Myocardium
Stroke
Myocardial Infarction
Apoptosis
Oxygen
Neurons
Mortality
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Parsa, C. J., Matsumoto, A., Kim, J., Riel, R. U., Pascal, L. S., Walton, G. B., ... Koch, W. J. (2003). A novel protective effect of erythropoietin in the infarcted heart. Journal of Clinical Investigation, 112(7), 999-1007. https://doi.org/10.1172/JCI18200

A novel protective effect of erythropoietin in the infarcted heart. / Parsa, Cyrus J.; Matsumoto, Akio; Kim, Jihee; Riel, Ryan U.; Pascal, Laura S.; Walton, G. Brant; Thompson, Richard B.; Petrofski, Jason A.; Annex, Brian H.; Stamler, Jonathan S.; Koch, Walter J.

In: Journal of Clinical Investigation, Vol. 112, No. 7, 10.2003, p. 999-1007.

Research output: Contribution to journalArticle

Parsa, CJ, Matsumoto, A, Kim, J, Riel, RU, Pascal, LS, Walton, GB, Thompson, RB, Petrofski, JA, Annex, BH, Stamler, JS & Koch, WJ 2003, 'A novel protective effect of erythropoietin in the infarcted heart', Journal of Clinical Investigation, vol. 112, no. 7, pp. 999-1007. https://doi.org/10.1172/JCI18200
Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB et al. A novel protective effect of erythropoietin in the infarcted heart. Journal of Clinical Investigation. 2003 Oct;112(7):999-1007. https://doi.org/10.1172/JCI18200
Parsa, Cyrus J. ; Matsumoto, Akio ; Kim, Jihee ; Riel, Ryan U. ; Pascal, Laura S. ; Walton, G. Brant ; Thompson, Richard B. ; Petrofski, Jason A. ; Annex, Brian H. ; Stamler, Jonathan S. ; Koch, Walter J. / A novel protective effect of erythropoietin in the infarcted heart. In: Journal of Clinical Investigation. 2003 ; Vol. 112, No. 7. pp. 999-1007.
@article{c6810bc3302941559f2c0f7d9c41b9ca,
title = "A novel protective effect of erythropoietin in the infarcted heart",
abstract = "Erythropoietin (EPO) has been shown to protect neurons from ischemic stroke, but can also increase thrombotic events and mortality rates in patients with ischemic heart disease. We reasoned that benefits of EPO might be offset by increases in hematocrit and evaluated the direct effects of EPO in the ischemic heart. We show that preconditioning with EPO protects H9c2 myoblasts in vitro and cardiomyocytes in vivo against ischemic injury. EPO treatment leads to significantly improved cardiac function following myocardial infarction. This protection is associated with mitigation of myocyte apoptosis, translating into more viable myocardium and less ventricular dysfunction. EPO-mediated myocyte survival appears to involve Akt activation. Importantly, cardioprotective effects of EPO were seen without an increase in hemarocrit (eliminating oxygen delivery as an etiologic factor in myocyte survival and function), demonstrating that EPO can directly protect the ischemic and infarcted heart.",
author = "Parsa, {Cyrus J.} and Akio Matsumoto and Jihee Kim and Riel, {Ryan U.} and Pascal, {Laura S.} and Walton, {G. Brant} and Thompson, {Richard B.} and Petrofski, {Jason A.} and Annex, {Brian H.} and Stamler, {Jonathan S.} and Koch, {Walter J.}",
year = "2003",
month = "10",
doi = "10.1172/JCI18200",
language = "English (US)",
volume = "112",
pages = "999--1007",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "7",

}

TY - JOUR

T1 - A novel protective effect of erythropoietin in the infarcted heart

AU - Parsa, Cyrus J.

AU - Matsumoto, Akio

AU - Kim, Jihee

AU - Riel, Ryan U.

AU - Pascal, Laura S.

AU - Walton, G. Brant

AU - Thompson, Richard B.

AU - Petrofski, Jason A.

AU - Annex, Brian H.

AU - Stamler, Jonathan S.

AU - Koch, Walter J.

PY - 2003/10

Y1 - 2003/10

N2 - Erythropoietin (EPO) has been shown to protect neurons from ischemic stroke, but can also increase thrombotic events and mortality rates in patients with ischemic heart disease. We reasoned that benefits of EPO might be offset by increases in hematocrit and evaluated the direct effects of EPO in the ischemic heart. We show that preconditioning with EPO protects H9c2 myoblasts in vitro and cardiomyocytes in vivo against ischemic injury. EPO treatment leads to significantly improved cardiac function following myocardial infarction. This protection is associated with mitigation of myocyte apoptosis, translating into more viable myocardium and less ventricular dysfunction. EPO-mediated myocyte survival appears to involve Akt activation. Importantly, cardioprotective effects of EPO were seen without an increase in hemarocrit (eliminating oxygen delivery as an etiologic factor in myocyte survival and function), demonstrating that EPO can directly protect the ischemic and infarcted heart.

AB - Erythropoietin (EPO) has been shown to protect neurons from ischemic stroke, but can also increase thrombotic events and mortality rates in patients with ischemic heart disease. We reasoned that benefits of EPO might be offset by increases in hematocrit and evaluated the direct effects of EPO in the ischemic heart. We show that preconditioning with EPO protects H9c2 myoblasts in vitro and cardiomyocytes in vivo against ischemic injury. EPO treatment leads to significantly improved cardiac function following myocardial infarction. This protection is associated with mitigation of myocyte apoptosis, translating into more viable myocardium and less ventricular dysfunction. EPO-mediated myocyte survival appears to involve Akt activation. Importantly, cardioprotective effects of EPO were seen without an increase in hemarocrit (eliminating oxygen delivery as an etiologic factor in myocyte survival and function), demonstrating that EPO can directly protect the ischemic and infarcted heart.

UR - http://www.scopus.com/inward/record.url?scp=85047691007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047691007&partnerID=8YFLogxK

U2 - 10.1172/JCI18200

DO - 10.1172/JCI18200

M3 - Article

C2 - 14523037

AN - SCOPUS:85047691007

VL - 112

SP - 999

EP - 1007

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 7

ER -